Eurofins Viracor has announced the launch of the cPass Coronavirus SARS-CoV-2 neutralising antibody test, which is designed to detect a recent or prior infection to the virus. The ELISA-based method detects neutralising antibodies to the receptor binding domain of the viral spike protein. The test has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for use by laboratories certified under clinical laboratory improvement amendments (CLIA) to perform highly complex tests.

BrainChip Holdings has announced that the Brainchip Research Institute in Perth and Biotome have entered into a research collaboration to develop highly accurate antibody tests for detecting infections. BrainChip’s Akida neuromorphic processor chip will be used to interpret sensor responses and to assess which responses are most representative for protective antibodies.

The Philippines Office of the Civil Defence (OCD) has been authorised to procure an initial 500,000 rapid antigen kits under its Inter-Agency Task Force for the Management of Emerging Infectious Diseases (IATF-EID) Resolution No. 108. As per the resolution, the OCD can use quick response funds to buy rapid antigen kits to ensure quick detection and tracing of infected individuals. The kits are approved by the FDA.